Mitochondrial redox regulation and myocardial ischemia-reperfusion injury
The treatment starts with a dose of 0.25 mg once weekly for four weeks, after which the dose is gradually increased until reaching a maintenance dose of 2.4 mg weekly
Now, it was a slow start though, Mike, because the history of drug development in obesity has been fraught with challenges
Once approved, here is what the pricing landscape looks like based on comparable drugs: Semaglutide (Wegovy) without insurance runs $1,300 to $1,600 per month in the US Tirzepatide (Zepbound) without insurance runs $1,000 to $1,300 per month in the US Retatrutide, as a next-generation triple agonist, will likely land at $1,200 to $1,800 per month at launch In Australia, the UK, and Canada, prices tend to be lower due to government drug pricing controls
We offer a free 15-minute strategy call to map out a plan for coaching with our dietitians to achieve optimal health